Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

380 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates.
Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, Firestone RA, Hellström I, Hellström KE. Trail PA, et al. Among authors: hellstrom i, hellstrom ke. Science. 1993 Jul 9;261(5118):212-5. doi: 10.1126/science.8327892. Science. 1993. PMID: 8327892
Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
Trail PA, Willner D, Knipe J, Henderson AJ, Lasch SJ, Zoeckler ME, TrailSmith MD, Doyle TW, King HD, Casazza AM, Braslawsky GR, Brown J, Hofstead SJ, Greenfield RS, Firestone RA, Mosure K, Kadow KF, Yang MB, Hellström KE, Hellström I. Trail PA, et al. Among authors: hellstrom i, hellstrom ke. Cancer Res. 1997 Jan 1;57(1):100-5. Cancer Res. 1997. PMID: 8988048
Possibilities for active immunotherapy of human cancer.
Hellström KE, Hellström I. Hellström KE, et al. Among authors: hellstrom i. Cancer Invest. 1992;10(4):285-93. doi: 10.3109/07357909209032753. Cancer Invest. 1992. PMID: 1378351 Review. No abstract available.
Immunoconjugates and immunotoxins for therapy of carcinomas.
Hellström I, Hellström KE, Siegall CB, Trail PA. Hellström I, et al. Among authors: hellstrom ke. Adv Pharmacol. 1995;33:349-88. doi: 10.1016/s1054-3589(08)60674-2. Adv Pharmacol. 1995. PMID: 7495675 Review. No abstract available.
380 results